Virtual Library

Start Your Search


Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center (ID 532)

      12:30 - 13:00  |  Presenting Author(s): IOANNA TSIOUPROU

      • Abstract
      • Slides


      Nowadays, cancer immunotherapy is rapidly evolving and monoclonal antibodies targeting the programmed death-1 receptor (PD-1) / PD ligand 1 (PD-L1) pathway have been approved for the treatment of NSCLC; however, there is lack of evidence regarding the current use of PD-L1 analysis in the everyday clinical practice.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      For this purpose we conducted a retrospective observational study in our lung cancer oncology unit. Eligible patients were adults of both sexes with non-small cell lung cancer who were treated in our department from April 2017 through December 2018. In total 123 patients were investigated regarding PD-L1 expression using the immunohistochemistry assay 22C3.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      108 out of 123 patients were male (87.8%) with a mean age of 67.5±9.3 years. Regarding smoking status there were 95 current smokers (77.2%), 27 former or never smokers (22%) and the mean pack-years were 45.9 ±36.78. Concerning lung cancer histology, 52 patients (42.3%) were diagnosed with squamous cell carcinoma, 63 (51.2%) with adenocarcinoma and 8 with NOS, adenosquamous and large cell carcinoma. At the time of initial diagnosis 59 of them (48%) were staged as IVA, 40 (32.5%) as stage I,II,III and 24 (19.5%) as IVB. Furthermore 11.4% had undergone surgical treatment and 13.8% of them radiotherapy. Out of the 123 specimens, 4 were non eligible for PD-L1 IHC analysis (<100 malignant cells/optical field). Sixty seven patients (54.5%) had PD-L1 TPS scores <1% and 20 (16%) had PD-L1 TPS scores ≥50%. Also 41 patients (33.3%) were treated with anti-PD-1 drugs (14 as first line, 19 as second and 8 as third). Eighteen of the patients who were treated with anti-PD-1 drugs were initially staged as IVA (43.9%) and 7 as IVB (17.1%). 14 out of 31 patients (20.4%) had disease control (8 SD and 6 PR/CR).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      In this retrospective analysis we found that the percentage of patients with PD-L1 expression ≥50% was 16% which is much lower than it was usually noticed in clinical trials. This could be probably attributed to the high percentage of patients with early or locally advanced tumors who were included.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      Pulmonary Department, Oncology Unit, Aristotle University of Thessaloniki.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.